EUROSETS
17.7.2024 11:13:26 CEST | Business Wire | Press release
The baby was affected by a viral infection, leaving him unable to breathe. Thanks to a state-of-the-art device, used for the first time in the world in the Caribbean, the medical-surgical team was able to save the infant.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716825866/en/
Colibrì, the lightest life-saving device that replaces the function of the heart and lungs (Photo: Eurosets)
The Colibri (hummingbird), one of the national symbols of Martinique, is also the name of an innovative, next-generation ECMO system, designed and manufactured by Eurosets, an Italian company based in the biomedical district of Medolla (MO), which enabled the medical-surgical team at Martinique University Hospital to save the life of a one-and-a-half-month-old child suffering from acute bronchiolitis.
The baby was born in Guadeloupe and weighed just 5kg. He was unable to breathe independently due to the viral infection, which subsequently led to heart failure. The infant was immediately transferred to the CHU de Martinique (CHUM), the only French hospital in the Caribbean with a third-level pediatric intensive care unit but, due the child's unstable condition, it was impossible to move him.
Following first-rate coordination with the neonatal intensive care unit at Guadeloupe University Hospital, the Martinique team from the UMAC (Unité Mobile d'Assistance Circulatoire) was able to travel to the neighboring island and connect the new ECMO system in the jugulo-carotid position to the newborn, allowing the infant to be transferred safely by helicopter.
The procedure was a success thanks to the seamless cooperation between Dr Xavier Beretta-Piccoli, pediatric intensive care specialist, and Dr Fabio Cuttone, head of pediatric cardiac surgery at the CHUM.
This intervention marked the world's first installation of a third-generation transportable device entirely designed and adapted for infants and children. The UMAC 972, consisting of a medical (intensive care specialist, cardiac surgeon) and paramedical (perfusionist) team, a pioneer in mobile circulatory assistance in the Caribbean archipelago and unique in terms of know-how and experience, played a vital role in the success of this medical treatment.
The infant was admitted to the CHUM pediatric intensive care unit. He received care and was attached to Colibri for five days until his lungs and heart functioned normally. Subsequently, having fully recovered from his bronchiolitis, the child was discharged from hospital and returned to Guadeloupe after 15 days in hospital. He will have to be monitored periodically, like all babies who have been in intensive care. He is now out of danger.
This ground-breaking treatment, the result of cooperation between the Martinique University Hospital, Eurosets, the CTM (Collectivité Territoriale de la Martinique) and European funding from React-UE (Recovery assistance for cohesion and the territories of Europe), finally provides the children of the Caribbean archipelago with a life-saving strategy at the forefront of technology.
Colibri is the world's lightest life-saving device capable of temporarily replacing cardiac and pulmonary functions. It is the only third-generation transportable system entirely designed and adapted to newborns and children.
In addition to adult patients, the device can be used on pediatric or even neonatal patients thanks to a dedicated centrifugal pump. The technology is suitable for use in a variety of therapeutic applications, including extracorporeal cardiopulmonary resuscitation (E-CPR) in cardiac arrest, extracorporeal membrane oxygenation (ECMO) and mechanical circulatory support (MCS).
Equipped with a centrifugal pump with magnetic levitation and a device capable of artificially oxygenating the blood, as well as offering excellent ergonomics, the Colibri is a high-performance circulatory assistance system, ideal in all situations in which intra- and extra-hospital transportability are crucial, including the most extreme rescue operations, such as airborne medical evacuations (by helicopter, passenger airline or military aircraft), scenarios that are common in the Caribbean region.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be crossreferenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716825866/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results30.7.2026 22:03:00 CEST | Press release
Second Quarter Financial Highlights Include: Revenue of $111.1 million, up 6.7% year over year Adjusted Revenue of $108.0 million, up 10.0% year over year Remaining Performance Obligations (RPO) of $636.9 million, up 8.0% year over year Adjusted Annualized Recurring Revenue of $401.1 million, up 8.1% year over year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730702735/en/ Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results “Second-quarter results and four consecutive quarters of improved growth metrics demonstrate strong demand for our core Rimini Support™ offering, increasing adop
Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service30.7.2026 22:01:00 CEST | Press release
The new service enables organizations to quickly and easily implement and operationalize a global, enterprise-wide governance, control, security and performance measurement solution for AI agent activity and workflows Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of Rimini Govern™ for AI, the newest offering in the company’s Rimini Govern portfolio of Governance, Risk and Compliance (GRC) solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730389723/en/ Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service The new managed service is delivered 24/7/365 through Rimini Street’s Global Command Centers by expert AI engineers to help organizations: Accelerate AI agent deployment Reduc
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples30.7.2026 21:03:00 CEST | Press release
Sample-to-report workflow generating single-cell RNA expression profiles using routine FFPE pathology slides from four institutions validated across 88 specimens and six cancer types One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded (FFPE) pathology specimens obtained in routine cancer care using the company’s proprietary platform, OneMap™. The study, conducted with collaborators at Centre Léon Bérard, Hôpital Bichat–Claude Bernard, Institut Curie, and Memorial Sloan Kettering Cancer Center, was released as a preprint on BiorXiv. “Every tumor is a unique ecosystem of many different types of cells, some cancerous, some not. Single cell profiling enables us to understand what those cells are, what they’re doing and potentially how that may impact treatment outcomes,” said Helena Yu, MD, thoracic medical onc
ARIS Recognized as a Leader in First Gartner® Magic Quadrant™ for Digital Twin of an Organization Platforms, Believes This Reinforces Need for Trusted Governance and Control of Enterprise AI30.7.2026 18:00:00 CEST | Press release
ARIS, the process context platform enabling enterprise AI deployment, today announced its recognition as a Leader in the inaugural Gartner Magic Quadrant for Digital Twin of An Organization (DTO) Platforms – where it believes agentic AI, autonomous workflows, and enterprise governance converge. As enterprises move from AI experimentation to autonomous agent deployment, a critical challenge emerges: how do you safely scale autonomous AI when the enterprise lacks a unified digital twin – a single source of truth for processes, data, governance, and outcomes? Gartner describes the DTO as a dynamic software model that relies on operational and contextual data to understand how an organization operationalizes its business model, connects with its current state, responds to changes, deploys resources, simulates future states and delivers customer value. "Enterprises are rightfully ambitious about agentic AI and autonomous workflows," said Guillaume Bacuvier, CEO of ARIS. "But they're discove
Kingswood Capital Management Raises $4 Billion Across Two Oversubscribed Middle-Market Funds30.7.2026 17:00:00 CEST | Press release
The firm’s fourth institutional fundraise more than doubles its assets under management, reaching over $7 billion Kingswood Capital Management, L.P. (together with its affiliates, “Kingswood”), a Los Angeles-based investment firm focused on the middle-market, today announced the final closing of Kingswood Capital Opportunities Fund IV, L.P. (together with its parallel fund, “Fund IV”), with total capital commitments of $3.1 billion, as well as Kingswood Capital Opportunities Small Cap Fund I, L.P. (together with its parallel fund, “Small Cap Fund I”), with total capital commitments of $900 million. These funds more than double Kingswood’s total assets under management (“AUM”) to over $7 billion. Fund IV represents the fourth institutional fundraise in five years for Kingswood and is more than double the size of Fund III. Both Fund IV and the inaugural Small Cap Fund I were significantly oversubscribed in just five weeks. Fund IV exceeded its initial target of $2.25 billion, while Small
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
